{"id":2966,"date":"2026-09-08T03:30:00","date_gmt":"2026-09-08T07:30:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2966"},"modified":"2026-09-08T20:40:30","modified_gmt":"2026-09-09T00:40:30","slug":"verekitug-phase-two-details-support-quarterly-asthma-dosing","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2966","title":{"rendered":"Verekitug Phase Two Details Support Quarterly Asthma Dosing"},"content":{"rendered":"

Evidence<\/strong> Same day detailed data catch-up · Published<\/strong> September 8, 2026 · Discovery<\/strong> September 8, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Positive<\/p>\n

\"Verekitug<\/p>\n

Summary<\/h4>\n

Upstream Bio presented full Phase II VALIANT results showing that verekitug 100 mg every 12 weeks reduced annualized severe-asthma exacerbations by 56% versus placebo (p<0.001) in a biomarker-unselected population. All three active regimens significantly reduced exacerbations, and lung function, exhaled nitric oxide and symptom control improved by Week 24. The same-day congress disclosure adds important quantitative context to the previously announced primary-endpoint result. It supports quarterly TSLP-receptor blockade, but the full dose-response, subgroup estimates, safety tables and rationale for advancing a higher 400 mg Phase III dose remain incomplete.<\/p>\n

What Happened<\/h4>\n

VALIANT randomized 478 adults with severe asthma in a global, double-blind, placebo-controlled, dose-ranging study. Enrollment did not require elevated eosinophils or other type-2 biomarkers. Every participant received at least 24 weeks of treatment, with earlier enrollees treated for up to 60 weeks. The 100 mg every-12-week arm reduced annualized asthma exacerbation rate by 56% versus placebo; the other two dose arms also achieved statistically significant reductions, although their numerical estimates were not included in the release.<\/p>\n

At Week 24, verekitug improved forced expiratory volume in one second, fractional exhaled nitric oxide and ACQ-6 symptom scores versus placebo, with changes visible by Week 2. The company described tolerability as favorable and said immunogenicity did not meaningfully affect safety or efficacy, but did not publish complete adverse-event or antidrug-antibody tables in the release. More than 90% of eligible participants entered the VALOUR extension. Phase III studies in severe asthma and chronic rhinosinusitis with nasal polyps are planned for early 2027 using 400 mg every 12 weeks.<\/p>\n

Deep Analysis<\/h4>\n

Receptor blockade may deliver broad quarterly control:<\/strong> A significant exacerbation reduction without biomarker enrichment and concordant changes in lung function, airway inflammation and symptoms support upstream pathway suppression. Quarterly dosing could lower treatment burden if efficacy persists through the interval. Exact efficacy by baseline eosinophils, FeNO, prior biologic use and dosing regimen is missing, so population breadth and dose stability cannot yet be tested independently.<\/p>\n

Dose selection and incomplete disclosure preserve material risk:<\/strong> The Phase III plan advances 400 mg every 12 weeks although the highlighted Phase II result uses 100 mg. A higher dose may maximize trough receptor coverage, but without public exposure-response, weight or phenotype analyses it may also indicate uncertainty about the minimum effective regimen. The company’s best-in-class objective is unsupported by an active comparator. Against a weak-signal interpretation, all active arms reportedly met the exacerbation endpoint and secondary measures moved in a mechanistically coherent direction.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts include 478 randomized participants, biomarker-unselected enrollment, a 56% AAER reduction at 100 mg every 12 weeks, significant effects in all active arms, early secondary-endpoint improvement and high extension uptake. Company claims include potential best-in-class efficacy and convenient at-home quarterly use. Missing facts include arm-level rates, confidence intervals, complete dose response, subgroup interactions, corticosteroid exposure, hospitalization, full safety, immunogenicity titers and Phase III dose justification.<\/p>\n

Company and Product Background<\/h4>\n

Upstream Bio is developing verekitug across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease. The program has exposed more than 500 participants across trials. Verekitug is a fully human IgG1 monoclonal antibody that binds the receptor for thymic stromal lymphopoietin rather than the ligand. TSLP is an epithelial alarm cytokine activated by allergens, infection and tissue injury; it sits upstream of multiple inflammatory programs involving IL-4, IL-5, IL-13, IL-17 and IgE. Receptor blockade is intended to interrupt these signals broadly.<\/p>\n

Severe asthma remains uncontrolled in a subset of patients despite high-dose inhaled therapy and available biologics, with exacerbations driving systemic corticosteroid use, hospitalization and cumulative morbidity. Clinical validation of the TSLP pathway exists, but receptor binding does not by itself prove greater efficacy than ligand neutralization. This full-data disclosure follows and extends the Phase III program-design update InSilens reported on September 2.<\/p>\n

InSilens Take<\/h4>\n

The congress data make verekitug a credible late-stage asthma program: exacerbations fell materially, multiple disease-activity measures agreed and efficacy did not require biomarker-selected enrollment. The score remains 4 rather than 5 because the disclosure is incomplete and the Phase III dose differs substantially from the highlighted Phase II regimen. No commercial or superiority conclusion follows from quarterly dosing alone. The next gating evidence is the full dose and subgroup dataset, regulatory agreement on Phase III design, and durable safety and efficacy in VALOUR.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — the full Phase II presentation advances a large asthma program toward Phase III with a differentiated quarterly receptor-targeting approach<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — randomized exacerbation and secondary endpoints favor verekitug across active regimens<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — design and headline endpoint data disclosed by the sponsor and linked to the registered study<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — missing arm-level, subgroup, exposure-response and safety detail limits comparative and population-wide conclusions<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Upstream Bio presented full Phase II VALIANT results showing that verekitug 100 mg every 12 weeks reduced annualized severe-asthma exacerbations by 56% versus placebo (p<0.001) in a biomarker-unselected population. All three active regimens significantly...\n<\/p>\n","protected":false},"author":1,"featured_media":2969,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[505,630,503,504],"class_list":["post-2966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-severe-asthma","tag-tslp","tag-upstream-bio","tag-verekitug"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2966"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2966\/revisions"}],"predecessor-version":[{"id":2998,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2966\/revisions\/2998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2969"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}